Blood Infection
The E.mbrace Study will assess the effectiveness and safety of an investigational vaccine in the prevention of blood infections in adults aged 60 or over. These blood infections can lead to serious complications such as dangerously low blood pressure or shock.
These infections are called an invasive (also known as systemic) infection, often referred to as an invasive E. coli disease (IED). Although IED affects all ages, adults aged 60 years and older have an increased risk of developing IED, which is further increased if you have had a urinary tract infection (UTI) in the past.
If you are found to be eligible to participate in the E.mbrace Study, on Day 1 you will receive the investigational vaccine or placebo (a vaccine that contains no active drug) in a single injection. You will also complete a minimum of eight study visits – some in person and some remote via telephone. The commitment period for the study is approximately three years. Visit type – whether in-person or remote – will be determined by the study team. Your study team will update you on the contacts and clinic visits required for your participation.
Study participants and/or their carer will be required to use a smartphone application to record and share information with their study team.
- Men and women
- 60 years of age or older
- Have had a UTI in the past two years
All FutureMeds trials are approved by an independent ethics committee.